ns 1619 has been researched along with bms 191011 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boissard, CG; Dworetzky, SI; Gao, Q; Gribkoff, VK; Martin, SW; Meanwell, NA; Moon, S; Natale, J; Ortiz, A; Pajor, L; Romine, JL; Starrett, JE; Yeleswaram, S | 1 |
| Ishii, K; Mori, A; Nakahara, T; Sakamoto, K; Suzuki, S | 1 |
2 other study(ies) available for ns 1619 and bms 191011
| Article | Year |
|---|---|
3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl ]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (maxi-K) channels, identification, solubility, and SAR.
Topics: Animals; Brain; Crystallography, X-Ray; Female; In Vitro Techniques; Ion Channel Gating; Large-Conductance Calcium-Activated Potassium Channels; Molecular Structure; Oocytes; Oxadiazoles; Patch-Clamp Techniques; Plasma; Rats; Rats, Inbred SHR; Solubility; Stroke; Structure-Activity Relationship; Xenopus laevis | 2007 |
BMS-191011, an opener of large-conductance Ca2+-activated potassium channels, dilates rat retinal arterioles in vivo.
Topics: Animals; Benzimidazoles; Dose-Response Relationship, Drug; Large-Conductance Calcium-Activated Potassium Channels; Male; Oxadiazoles; Rats; Rats, Wistar; Retina; Retinal Artery; Vasodilation; Vasodilator Agents | 2011 |